Catalent's revenue for fiscal first quarter ended Sept. 30 was $1.02 billion, marginally below analysts' estimates of $1.06 ...

BRUSSELS/LONDON (Reuters) -EU antitrust regulators will decide by Dec. 6 whether to clear Novo Holdings' acquisition of ...

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

Catalent Inc ( (CTLT)) has released its Q1 earnings. Here is a breakdown of the information Catalent Inc presented to its investors. Catalent Inc., a leading global contract development and ...

Catalent (CTLT) delivered earnings and revenue surprises of -218.18% and 5.28%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Catalent (NYSE:CTLT), a contract development and manufacturing organization (CDMO), reported results for Q1 of fiscal 2025 that missed analyst expectations.

Reports Q1 revenue $ $1.02B , consensus $1.06B…Q1’25 Adjusted EBITDA of $125 million increased 11% as reported, or 10% in constant ...

SOMERSET, N.J. (AP) — SOMERSET, N.J. (AP) — Catalent Inc. (CTLT) on Tuesday reported a loss of $129 million in its fiscal first quarter. The Somerset, New Jersey-based company said it had a loss of 71 ...

On Monday, Catalent Inc (CTLT) stock saw a decline, ending the day at $58.69 which represents a decrease of $-0.04 or -0.07% from the prior close of $58.73. The stock opened at $58.92 and touched a ...

Roche CEO opposes Novo Nordisk's acquisition of Catalent, citing concerns about competition in the ...

The CEO of pharmaceuticals giant Roche said authorities should block the takeover of contract drug manufacturer Catalent by ...